Tecan has launched a fully automated affinity purification solution for the extraction of large biomolecules, such as proteins, antibodies and antibody-drug conjugates. This set-up takes advantage of the new Thermo Scientific™ MSIA™ Streptavidin EVO microcolumns, which have been specifically designed for use on Tecan’s proven Freedom EVO® platform. In combination with the Freedom EVO workstation, this solution is ideal for high throughput applications in biopharmaceutical development, clinical research and anti-doping laboratories.
Housed within a pipette tip, the proprietary MSIA microcolumns are densely coated with streptavidin for affinity purification using any biotinylated ligand, even at low concentrations. Compared to traditional resin- and bead-based methods, this new approach offers improved analytical sensitivity and lower background noise, while the automated workflow enables easier method standardization and transfer between labs. This allows multi-analyte characterization over a wide dynamic range of three orders of magnitude, while maintaining good reproducibility of <5 %CV*.
Preeti Saini, Product...
“Our combined solution will provide these laboratories with faster assay development, scalable sample turnover and surety of data quality and consistency,” added Rohit Shroff, Product Manager for Tecan. “By combining our well-established Freedom EVO workstations with MSIA technology, we can better cater to the high volume bioanalytical research market.”
About Tecan
Tecan is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2014, Tecan generated sales of CHF 400 million (USD 437 million; EUR 331 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).
Interested in reading more?
The Scientist ARCHIVES
Become a Member of
